Interestingly, while cancer and atherosclerosis share similarities in their inflammatory-dependent pathophysiology, ICI mAbs, specifically CTLA-4 and PD-1–PD-L1 blocking antibodies, have been shown to increase cardiovascular events associated with atherosclerosis (160). This evidence concerns the gene PDCD1 and atherosclerosis.